首页 | 本学科首页   官方微博 | 高级检索  
     


Pharmacokinetics of 10 mg of mifepristone
Authors:Leminen Riikka  Ranta Sirpa  von Hertzen Helena  Oehler Joachim  Heikinheimo Oskari
Affiliation:

a Department of Obstetrics and Gynecology, University of Helsinki, P.O. Box 140, SF-00029, HUS, Helsinki, Finland

b Institute of Biomedicine, University of Helsinki, Helsinki, Finland

c World Health Organisation, Department of Reproductive Health Research, Geneva, Switzerland

d The Concept Foundation, Bangkok, Thailand

Abstract:
The results of several randomized studies have verified the efficacy of 10 mg mifepristone in emergency contraception. In the present study we characterized the pharmacokinetics of 10 mg mifepristone. Eight healthy female volunteers received a single oral dose of mifepristone on the day 10 or 11 of their menstrual cycle. Blood samples were collected at 0, 1, 2, 4 and 8 h, daily for the next 6 days and on day 10 after mifepristone. Mifepristone concentrations were determined by radioimmunoassay preceded by column chromatography. A peak level of 1.41 ± 0.31 μmol/L (mean ± SD) was measured at 1 h. Individual elimination phase half-lives varied from 15.3 to 26.8 h, the mean (± SD) value being 19.6 ± 4.50 h. Serum mifepristone concentrations exceeded 10 nmol/L in all volunteers for an average of 4.9 days. The pharmacokinetic data on 10 mg mifepristone are in line with previous pharmacokinetic and clinical data, and encourage further development of the 10-mg dose in emergency contraception.
Keywords:Radioimmunoassay   Emergency contraception   Inhibition of ovulation   Dose–response relationships
本文献已被 ScienceDirect PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号